Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $21,323.58 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Peter Kaiser sold 2,974 shares of the stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $7.17, for a total transaction of $21,323.58. Following the completion of the sale, the insider now owns 207,104 shares of the company's stock, valued at approximately $1,484,935.68. The trade was a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Ocular Therapeutix Trading Down 1.6%

Shares of NASDAQ:OCUL traded down $0.13 during mid-day trading on Friday, reaching $8.01. 2,177,691 shares of the company were exchanged, compared to its average volume of 1,399,863. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -6.07 and a beta of 1.51. The firm's 50-day simple moving average is $7.37 and its 200 day simple moving average is $7.90. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analysts' expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Ocular Therapeutix

A number of hedge funds have recently made changes to their positions in OCUL. GF Fund Management CO. LTD. purchased a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $28,000. Brooklyn Investment Group boosted its position in Ocular Therapeutix by 151.5% in the 1st quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 3,155 shares during the period. Atlas Capital Advisors Inc. purchased a new position in Ocular Therapeutix in the 4th quarter valued at approximately $43,000. AlphaQuest LLC purchased a new position in Ocular Therapeutix in the 4th quarter valued at approximately $53,000. Finally, GAMMA Investing LLC boosted its position in Ocular Therapeutix by 6,760.0% in the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 8,112 shares during the period. Hedge funds and other institutional investors own 59.21% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on OCUL. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Needham & Company LLC dropped their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target for the company. William Blair began coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an "outperform" rating for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Ocular Therapeutix presently has an average rating of "Moderate Buy" and an average target price of $16.25.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.